Constipation on Ozempic, Mounjaro or Zepbound: how common, and what helps
Reviewed 13 sourcesPublished by PepVault
Constipation on Ozempic, Wegovy, Mounjaro and Zepbound: each label's rate against placebo, when it starts, why it lasts for weeks, and what helps.

- Last reviewed
- Sources
- 13
- Questions
- 7
- Compounds
- 3
The short answer
Constipation affects about one in four people on Wegovy 2.4 mg (24% against 11% on placebo) and 11% to 17% on Zepbound (against 5%), fewer at the diabetes doses of Ozempic and Mounjaro. It starts early and, unlike diarrhea, lingers: an episode lasted a median of 47 days on semaglutide. Water, fiber from food and walking come first, then a laxative your prescriber or pharmacist suggests.
Evidence: FDA prescribing information for all four medicines, built on randomized placebo-controlled trials in people; trial registry results from STEP 1, SURMOUNT-1 and SURMOUNT-5; a sponsor-funded pooled analysis of the STEP trials for timing and duration; three US health-record studies; and an expert consensus and a joint society advisory for the practical steps.

How common is constipation on Ozempic, Wegovy, Mounjaro and Zepbound?
Common on all four, and far more common at the weight-loss doses. Ozempic and Wegovy are semaglutide; Mounjaro and Zepbound are tirzepatide. Each US label counts the share of people in its placebo-controlled trials who reported constipation at least once, set against a placebo group on a dummy shot1234:
| Medicine and dose | Trials behind the number | Constipation on the drug | Constipation on placebo |
|---|---|---|---|
| Ozempic 0.5 mg | 2 type 2 diabetes trials, 32.9 weeks on average | 5% | 1.5% |
| Ozempic 1 mg | The same 2 trials | 3.1% | 1.5% |
| Mounjaro 5 mg | 2 type 2 diabetes trials, 36.6 weeks on average | 6% | 1% |
| Mounjaro 10 mg | The same 2 trials | 6% | 1% |
| Mounjaro 15 mg | The same 2 trials | 7% | 1% |
| Wegovy 2.4 mg | 3 weight trials, up to 68 weeks | 24% | 11% |
| Wegovy 7.2 mg (19% on its 2.4 mg arm) | 2 weight trials, 72 weeks | 20% | 8% |
| Zepbound 5 mg | 2 weight trials, up to 72 weeks | 17% | 5% |
| Zepbound 10 mg | The same 2 trials | 14% | 5% |
| Zepbound 15 mg | The same 2 trials | 11% | 5% |
Two things stand out. The weight doses add far more over placebo than the diabetes doses do. And on tirzepatide, constipation is the one stomach effect that falls as the dose rises: 17%, 14% and 11% on Zepbound4, and the same shape in SURMOUNT-1's registry results, 17.9%, 18.4% and 12.7% against 5.9% on placebo9. No source we found explains why. The labels warn that rates from different trials cannot be compared directly13. When both drugs ran in one 72-week trial (SURMOUNT-5), at their top weight doses or the highest each person tolerated, constipation was close to a tie: 27.0% on tirzepatide and 28.5% on semaglutide10.
The Wegovy pill (25 mg) had side effects of similar types and rates to the 2.4 mg shot. In teenagers on Wegovy, constipation affected 6% against 2% on placebo. Zepbound's count includes reports of hard stools24.

Why do health records show far less GLP-1 constipation than the trials?
Because they count different things. A trial asks everyone at every visit and counts any report, however mild. A health record counts what a doctor wrote down. In the US All of Us research program, 31.6% of 11,656 GLP-1 users had constipation in their records at some point, against 26.8% of non-users, all of them people with obesity: a high share, but most of it was not new11.
For constipation that was new after starting, the same study matched users to similar non-users. In the first year, GLP-1 users got a new constipation diagnosis at a rate of 3.34 per 100 person-years (person-years means people times years followed), a mean of 141 days after the first dose. The risk was about 1.5 times that of matched non-users. By drug, the rate was 2.90 on semaglutide and 1.81 on tirzepatide11. So constipation in the trials is common and mostly mild; constipation that reaches a doctor is a small minority.
When does GLP-1 constipation start, and how long does it last?
It starts early and then holds steady, unlike nausea. In the pooled STEP 1 to 3 weight trials on semaglutide 2.4 mg, the share of people with constipation at any one time climbed and then levelled off at about week 10, while nausea, diarrhea and vomiting kept rising to a peak near week 205. A Spanish expert panel's review puts the start in the first 16 weeks, particularly the first 28 days6.
The striking number is the length. Each episode was timed from start to end: the median, the middle value, was 47 days on semaglutide against 35 days on placebo, while diarrhea lasted 3 days and vomiting 25. The registries show the other half of the pattern: few people had it again and again. We divided each trial's reported episodes by the number of people who had any8910:
| Trial and group | People with constipation | Episodes reported | Episodes per person who had it (our division) |
|---|---|---|---|
| STEP 1, semaglutide 2.4 mg (75 weeks) | 305 of 1,306 (23.4%) | 389 | 1.3 |
| STEP 1, placebo | 62 of 655 (9.5%) | 73 | 1.2 |
| SURMOUNT-1, tirzepatide 5 mg (up to 193 weeks) | 113 of 630 (17.9%) | 129 | 1.1 |
| SURMOUNT-1, tirzepatide 10 mg | 117 of 636 (18.4%) | 148 | 1.3 |
| SURMOUNT-1, tirzepatide 15 mg | 80 of 630 (12.7%) | 100 | 1.3 |
| SURMOUNT-1, placebo | 38 of 643 (5.9%) | 49 | 1.3 |
| SURMOUNT-5, tirzepatide (72 weeks) | 101 of 374 (27.0%) | 179 | 1.8 |
| SURMOUNT-5, semaglutide | 107 of 376 (28.5%) | 167 | 1.6 |
So a person who got constipated had one or two episodes on average, about as many as on placebo; on the same STEP 1 count, diarrhea came about twice per person (our guide to diarrhea on a GLP-1 has those numbers). Read each trial on its own: the windows differ, and SURMOUNT-5 was open-label, so everyone knew which drug they took10. For people who stayed on semaglutide after a 20-week climb in STEP 4, constipation became less common over time5. No primary source we found gives an episode length for tirzepatide.
PepVault's dose log keeps each weekly shot with its date and the step-ups your prescriber set, as you enter them, so you can see which step a slow week followed. Log it in PepVault
Why do GLP-1s cause constipation?
All four labels state that the medicine slows how fast the stomach empties1234. The STEP analysis's authors add that changes in how fast food moves through the lower gut may explain constipation, that the proof is still thin, and that constipation may last longer because of these drugs' effect on gut movement5.
Two everyday reasons stack on top. Feeling full for longer, people tend to drink less water, which the expert panel names as a cause6. And eating less means less going through: a joint advisory from four US lifestyle-medicine, nutrition and obesity societies calls constipation common with weight loss itself, and notes that meals high in protein or fat slow the stomach further7.
Is constipation on a GLP-1 serious?
Rarely. In the STEP 1 to 3 trials, 98.1% of all stomach side effects on semaglutide 2.4 mg were mild or moderate and 99.5% were not serious5. Serious constipation was counted in 1 of 1,306 people on semaglutide in STEP 18, and in 1 of 636 on tirzepatide 10 mg in SURMOUNT-19.
After approval, all four labels list rare reports of ileus (the bowel stops moving), intestinal blockage and severe constipation with impacted stool1234. In US insurance records of adults with type 2 diabetes, severe gut-motility problems of this kind ran at 1.02 per 100 person-years on GLP-1 medicines against 0.75 on another diabetes drug class, SGLT-2 inhibitors12. Among GLP-1 users with type 2 diabetes who started an opioid painkiller, 0.33% to 0.51% had severe constipation, a blockage or a stalled stomach within 30 days, highest on oxycodone13. Tell your prescriber about any painkiller you start.
What helps with constipation on a GLP-1?
Fluids, fiber and movement first, from the first weeks. These come from the expert panel's recommendations and the joint advisory67:
- Drink generous amounts of water or other sugar-free drinks through the day, even when you do not feel thirsty: fullness makes it easy to drink less.
- Get enough fiber from food, and raise it gradually: prunes and other dried fruit, vegetables, beans and whole grains.
- Lean on lighter, watery foods such as fruit and vegetables, which leave the stomach faster.
- If it lingers, ease off very rich, fatty or protein-heavy meals for a while, since they slow the stomach further; spread your protein across the day rather than dropping it.
- Walk or move more each day.
- Keep a short diary of stools, food and dose to see whether it is easing.
When food is not enough, the advisory lists the next options: daily magnesium, adjusted to keep stools regular (magnesium citrate is the form it names), fiber supplements, polyethylene glycol 3350 (an over-the-counter laxative that holds water in the stool), and stool softeners to avoid straining7. Our guide to magnesium glycinate and citrate covers the forms. The panel adds that a lower GLP-1 dose is an option if it worsens6, the trials let people stay up to 8 weeks on a dose so stomach effects could settle7, and the Wegovy shot's label tells prescribers to consider waiting 4 more weeks before the next step if a dose is not tolerated2. The advisory also notes that some anti-nausea medicines, such as ondansetron, can worsen constipation7. Which laxative, and any dose change, is for your prescriber or pharmacist to decide.
Commonly reported: constipation is a regular theme in open write-ups; on our reports pages, 2 of 41 people on semaglutide and 5 of 77 on tirzepatide mentioned it.
When to get help The Medication Guides ask you to tell your prescriber about stomach problems that are severe or will not go away, and to stop the medicine and call right away for severe pain in the stomach area that will not go away, with or without vomiting1234.
How do I keep track of constipation on a GLP-1?
Note the day it starts, how strong it is, what you ate and drank, and which dose you were on. A few weeks of notes show whether it is easing, as it did for most people in the trials, or holding on, which is the pattern to bring to your prescriber.
PepVault's side-effect log records each symptom with the compound, a severity from minimal to very severe, the date and a note. On tirzepatide, constipation is one tap in the quick list. Log it in PepVault
PepVault's food log counts the fiber in each meal and shows the day's total against a daily fiber target set from your calorie target. Track your food in PepVault
The full side-effect picture for each medicine is in our guides to Ozempic and Wegovy side effects, Mounjaro and Zepbound side effects, and what to eat on a GLP-1.
Sources
- OZEMPIC (semaglutide) injection prescribing information, DailyMed (SPL version 20; published on DailyMed June 10, 2026). Sections 6.1 (Table 1), 6.2, 7.2 and the Medication Guide. dailymed.nlm.nih.gov
- WEGOVY (semaglutide) injection and tablets prescribing information, DailyMed (SPL version 19; published on DailyMed June 30, 2026). Sections 2.2, 6.1 (Tables 3, 4 and 5), 6.2, 7 and the Medication Guide. dailymed.nlm.nih.gov
- MOUNJARO (tirzepatide) injection prescribing information, DailyMed (SPL version 40; published on DailyMed September 2, 2026). Sections 6.1 (Table 1), 6.2, 7 and the Medication Guide. dailymed.nlm.nih.gov
- ZEPBOUND (tirzepatide) injection prescribing information, DailyMed (SPL version 40; published on DailyMed September 2, 2026). Sections 6.1 (Table 1), 6.2, 7 and the Medication Guide. dailymed.nlm.nih.gov
- Wharton S et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24:94-105. PubMed 34514682
- Gorgojo-Martínez JJ et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12:145. PubMed 36614945
- Mozaffarian D et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025;33(8):1475-1503. PubMed 40445127
- ClinicalTrials.gov NCT03548935 (STEP 1; sponsor Novo Nordisk A/S). Results: adverse events, week 0 to 75. clinicaltrials.gov
- ClinicalTrials.gov NCT04184622 (SURMOUNT-1; sponsor Eli Lilly and Company). Results: adverse events, baseline up to week 193. clinicaltrials.gov
- ClinicalTrials.gov NCT05822830 (SURMOUNT-5; sponsor Eli Lilly and Company). Results: adverse events, baseline up to week 72. clinicaltrials.gov
- Chang M, Wang K, Berschback M, Staller K. High prevalence and low incidence of constipation among glucagon-like peptide-1 receptor agonist users. Clin Gastroenterol Hepatol. 2026 (online June 2). PubMed 42235870
- Alkabbani W et al. Glucagon-like peptide-1 based therapies and the risk of severe gastrointestinal motility adverse events: a cohort study. Diabetes Obes Metab. 2026;28(8):7494-7504. PubMed 42244136
- Bea S et al. Comparative short-term risk of severe gastrointestinal events associated with opioid type among patients receiving glucagon-like peptide 1 receptor agonists. Diabetes Care. 2026;49(11):2050-2059. PubMed 42684335
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.